Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
Rhea-AI Summary
Appili Therapeutics (OTC:APLIF) reported fiscal 2026 results, highlighting U.S. commercial progress for LIKMEZ, a growing non-dilutive funding base, and pipeline advances. A new US$40 million NIAID contract supports antifungal vaccine VXV-01 through IND and Phase 1 trials.
ATI-1801’s FDA-aligned bridging strategy may allow NDA submission without new efficacy trials. ATI-1701 achieved GMP drug manufacture under a ~US$14 million USAFA agreement. For FYE 2026, net loss was $4.2M, cash was $0.04M, and financial statements include a going concern note.
Positive
- US$40 million NIAID contract for VXV-01 through IND and Phase 1
- Over US$66 million in cumulative U.S. government funding secured to date
- LIKMEZ royalties and milestones provide growing commercial revenue stream
- Additional LIKMEZ patents extend protection in U.S. and Mexico to 2039
- ATI-1701 GMP drug substance and product manufactured, meeting release specs
- Research and development expenses decreased by $3 million year-over-year
Negative
- Net loss increased to $4.2 million from $2.6 million year-over-year
- Cash balance fell to $0.04 million from $1.2 million, with going concern note
- Government assistance decreased by $7 million versus prior year
- Other income decreased by $0.9 million, mainly from lower waiver fees
- LZH and Bloom Burton loans extended but amounts due starting June 30, 2026
News Market Reaction – APLIF
In the Jun 30 session, APLIF declined 2.65%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market
US
HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.
"Fiscal year 2026 marked a significant transition for Appili as we advanced commercial-stage programs and continued to build our non-dilutive funding base,” said Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics. "With LIKMEZ gaining traction in the U.S., our pipeline progressing with government backing, and US
“With a clear roadmap in place, the Company is focused on growing LIKMEZ, advancing our funded pipeline programs, and securing additional non-dilutive and equity capital as we move into fiscal 2027” adds Dr. Don Cilla.
ATI-1801, Topical Antiparasitic with Aligned Regulatory Path
ATI-1801 is a novel topical formulation of paromomycin (
Appili licensed the exclusive worldwide rights to ATI-1801 from the U.S. Army Medical Materiel Development Activity and holds a complete clinical dossier, including a randomized, vehicle-controlled Phase 3 study conducted in Tunisia that met its primary endpoint, with ATI-1801 demonstrating a significant improvement in the rate of clinical cure of the index lesion compared to vehicle at 6 months.
Following Appili’s Type B meeting with the U.S. Food and Drug Administration (“FDA”), the agency agreed with the Company’s proposed scientific bridging strategy between previously used clinical trial material and new drug product batches. This approach centers on developing a validated in vitro release test and manufacturing a new reference standard to support an NDA submission without the need for additional clinical efficacy studies, potentially accelerating time to registration.
ATI-1801 has received Orphan Drug Designation from the FDA for the treatment of certain forms of cutaneous leishmaniasis, and Appili believes the program may be eligible to receive a Priority Review Voucher (“PRV”) upon approval. Appili is actively pursuing non-dilutive funding and partnership opportunities with NGOs and government agencies to implement the agreed-upon regulatory strategy and complete remaining development work.
LIKMEZ® (ATI-1501), Seeing Commercial Momentum in the U.S. Market
LIKMEZ® (metronidazole oral suspension, 500 mg/5 mL), Appili’s licensed, taste-masked oral liquid formulation of metronidazole, is being commercialized in the U.S. by Saptalis Pharmaceuticals, LLC (“Saptalis”). LIKMEZ is the first and only FDA-approved, ready-to-use liquid oral suspension of metronidazole, designed for patients who have difficulty swallowing tablets or who are sensitive to taste.
Saptalis re-launched LIKMEZ in May 2025, and the product has demonstrated steady sales growth reflecting increasing clinician adoption and patient demand. Under the agreement with Saptalis, Appili receives sales-based milestone payments and royalties, providing a growing source of commercial revenue.
In April 2025, additional patents covering the composition and preparation methods for LIKMEZ were issued in the U.S. and Mexico, extending patent protection through 2039 and further strengthening the commercial profile of the product.
ATI-1701, Critical Biodefense Vaccine Candidate
ATI-1701 is Appili’s live-attenuated vaccine candidate for the prevention of tularemia, a Category A pathogen-associated disease identified by the U.S. National Institutes of Health as a serious threat to national security and public health. There is currently no approved vaccine for tularemia in the U.S. or other major global markets.
Appili holds exclusive worldwide rights to ATI-1701 and is advancing the program under a cooperative agreement with the U.S. Air Force Academy (“USAFA”), in collaboration with the Defense Threat Reduction Agency. USAFA has awarded approximately US
During FYE 2026, Appili achieved a key operational milestone with the successful GMP manufacture of ATI-1701 drug substance and drug product at the Walter Reed Army Institute of Research. The drug product met all release specifications and may be dispositioned for use in future clinical studies. The period of performance under the agreement with USAFA has been extended to August 31, 2026.
Appili continued to engage with global biodefense stakeholders, with presentations at the NATO CBRN Conference and the U.S. Medical CBRN Defense Consortium Annual Membership Meeting, reinforcing ATI-1701's profile as a critical biodefense asset. The Company remains focused on securing additional non-dilutive funding to support an Investigational New Drug application and advance ATI-1701 to the clinic.
Subject to the renewal of certain U.S. legislation, Appili believes that ATI-1701 may be eligible to receive a PRV, if approved by the FDA.
VXV-01, NIAID-Funded Antifungal Vaccine Program
VXV-01 is a novel, dual-antigen vaccine targeting invasive Candida infections, being advanced by Appili in collaboration with Vitalex Biosciences (“Vitalex”).
In October 2025, Appili and Vitalex announced a contract by the U.S. National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health, valued at up to US
Under an exclusive option agreement with Vitalex, Appili retains the right to acquire full worldwide rights to VXV-01, positioning the Company to transition from development lead to asset owner upon achievement of defined milestones.
Globally, an estimated 6.5 million people are affected by invasive fungal infections annually, resulting in approximately 3.8 million deaths, and there are currently no approved fungal vaccines for human use, underscoring the significant unmet need VXV-01 aims to address.
Update on U.S. Federal Government Funding Proposals
Appili continues to execute a non-dilutive funding strategy, leveraging its expertise in government contracting to advance its infectious disease and biodefense programs.
Since inception, the Company has secured over US
Lender Extensions
Appili has secured extensions to the amounts due under each of (1) the amended and restated secured loan agreement with Long Zone Holdings Inc. (the “LZH Loan”) and (2) the unsecured promissory notes with Bloom Burton & Co. Inc. (the “Bloom Burton Loan”). Pursuant to the terms of such extensions, all amounts owing under the Bloom Burton Loan, together with all accrued and unpaid interest, will be due on June 30, 2026. All amounts owing under the LZH Loan, together with all accrued and unpaid interest, will be due on June 30, 2026 unless Appili completes an equity financing with minimum gross proceeds of at least CAD
Annual Financial Results
The Company prepares its financial statements in accordance with IFRS as issued by the International Accounting Standard Board and Part I of Chartered Professional Accountants of Canada Handbook – Accounting.
The net loss and comprehensive loss of
On March 31, 2026, the Company had cash of
As of June 25, 2026, the Company had 132,366,120 issued and outstanding Common Shares, 11,910,281 stock options and 41,368,000 warrants outstanding.
This press release should be read in conjunction with the Company’s audited annual consolidated financial statements for the FYE 2026, and the related MD&A, copies of which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.
Forward looking statements
This news release contains “forward-looking statements”, including with respect to the potential for partnered projects to be developed, the potential that Appili will receive government awards and / or contracts related to its proposal submissions, further anticipated milestones and the timing thereof, the Company’s development plans and timelines with respect to ATI-1501, ATI-1701, ATI-1801 and VXV-01, the timing of any milestone and/or royalty payments in respect of ATI-1501, the Company’s expectations of PRV eligibility for certain of its programs and the Company’s expectations with respect to its ability to operate as a going concern and satisfy its ongoing working capital requirements. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, (i) the risk that the Company may not be reimbursed for services provided under approved US government contracts or secure additional government funding in respect of any proposal submitted prior to the date hereof, (ii) risks relating to the ability of the Company to repay the LZH Loan and the Bloom Burton Loan as and when they become due or, alternatively, the ability of the Company to secure extensions to the maturity date thereof, and (iii) those risks listed in the annual information form of the Company dated June 26, 2026, and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.
Media Contact:
Jenna McNeil, Communications Manager
Appili Therapeutics
E: JMcNeil@AppiliTherapeutics.com
Investor Relations Contact:
Don Cilla, President and CEO
Appili Therapeutics
E: Info@AppiliTherapeutics.com
